Compare 3M Company (MMM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Merck & Co., Inc. — how do they compare? 3M Company trades at $183.06 (market cap $93.88B), while Merck & Co., Inc. trades at $130.46 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 3.4× 3M Company's market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| MMM | MRK | |
|---|---|---|
Market Cap | $93.88B | $323.00B |
Sector | Industrials | Health |
52-Week High | $183.13 | $131.84 |
52-Week Low | $141.10 | $77.60 |
Enterprise Value | $103.10B | $369.77B |
Dividend Yield | 1.71% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $182.89, up 1.21% today, with a bullish technical signal from moving averages and strong support at $180. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding the $2.25 estimate, and raised its full-year guidance. Revenue for 2025 was $24.95 billion, with a net income margin of 11.9% and a high return on equity of 82.77%. Recent news highlights strength in the Safety & Industrial segment and a partnership with Microsoft on EBO technology.
The outlook is positive due to operational improvements and innovation, but risks include litigation liabilities and macroeconomic pressures. Analysts are mixed with a consensus price target of $173.00, below the current price, suggesting cautious optimism. The stock's valuation metrics, such as a P/E of 32.49, indicate it may be fully priced, requiring careful monitoring of execution against raised guidance.
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
